Bortezomib (Velcade?) in the treatment of multiple myeloma

Antonia Field-Smith; Gareth J Morgan; Faith E Davies

doi:10.2147/tcrm.2006.2.3.271

journal article Jan 01, 2006

Bortezomib (Velcade?) in the treatment of multiple myeloma

Antonia Field-Smith Gareth J Morgan Faith E Davies

Therapeutics and Clinical Risk Management Vol. 2 No. 3 pp. 271-279 · Informa UK Limited

View at Publisher Save 10.2147/tcrm.2006.2.3.271

Topics

No keywords indexed for this article. Browse by subject →

References

46

[1]

Adams J Cancer Res (1999)

[2]

10.1038/nrc1361

[3]

Aghajanian C Clin Cancer Res (2002)

[4]

Alexanian R Blood (2004) 10.1182/blood.v104.11.210.210

[5]

10.1111/j.1365-2141.2005.05514.x

[6]

10.1200/jco.2005.03.2383

[7]

10.1046/j.1365-2141.1998.00930.x

[8]

10.1182/blood-2005-02-0522

[9]

10.1182/blood-2005-02-0669

[10]

[EMEA] European Medicines Agency. 2004. European public assessment report: scientific discussion. The committee for medicinal products for human use [online]. Accessed 20 March 2006. URL: http:// www.emea.eu.int/humandocs/Humans/EPAR/velcade/velcade.htm.

[11]

10.1182/blood-2005-04-1588

[12]

10.1200/jco.2005.03.108

[13]

10.1182/blood-2003-12-4174

[14]

Hideshima T Cancer Res (2001)

[15]

10.1182/blood-2002-08-2543

[16]

10.1111/j.1365-2141.2004.05188.x

[17]

10.1002/cncr.20888

[18]

Jagannath S Blood (2005) 10.1182/blood.v106.11.783.783

[19]

10.1038/nrc780

[20]

Kropff M Blood (2005) 10.1182/blood.v106.11.2549.2549

[21]

10.1158/0008-5472.can-04-3684

[22]

LeBlanc R Cancer Res (2002)

[23]

10.1182/blood-2005-03-1173

[24]

10.1002/cncr.21414

[25]

Ma MH Clin Cancer Res (2003)

[26]

Mateos MV Blood (2005) 10.1182/blood.v106.11.786.786

[27]

10.1182/blood-2002-06-1768

[28]

[NCI] National Cancer Institute. 2003. Common terminology criteria for adverse events v3.0 [online]. Accessed 12 October 2005. URL: http:/ /ctep.cancer.gov/forms/CTCAEv3.pdf.

[29]

10.1111/j.1365-2141.2005.05519.x

[30]

10.1200/jco.2002.01.133

[31]

10.1182/blood-2004-07-2911

[32]

Palumbo A Blood (2005) 10.1182/blood.v106.11.4643.4643

[33]

Popat R Blood (2005) 10.1182/blood.v106.11.2555.2555

[34]

10.1200/jco.2005.11.030

[35]

Reece DE Blood (2005) 10.1182/blood.v106.11.2556.2556

[36]

10.1056/nejmoa030288

[37]

10.1182/blood-2005-02-0691

[38]

Richardson PG Hematol J (2004)

[39]

10.1056/nejmoa043445

[40]

Richardson PG Blood (2005) 10.1182/blood.v106.11.2547.2547

[41]

Richardson P Blood (2005) 10.1182/blood.v106.11.365.365

[42]

10.1001/archinte.165.4.464

[43]

San Miguel JF Blood (2005) 10.1182/blood.v106.11.366.366

[44]

Suvannasankha A Blood (2005) 10.1182/blood.v106.11.2562.2562

[45]

Wang M Blood (2005) 10.1182/blood.v106.11.784.784

[46]

Zangari M Blood (2005) 10.1182/blood.v106.11.2552.2552

Cited By

213

Synergistic cytotoxic effect of doxorubicin and bortezomib on lung cancer cell lines using 2D and 3D models

Mohammad Alwahsh, Osama H. Abusara · 2026

Cancer Treatment and Research Commu...

Effect of Bortezomib, Daptomycin and Their Combination on Antiproliferation in U266 Multiple Myeloma Cell Line

Kübra Yılmaz, Ahmet Ozan Kaleci · 2025

Cumhuriyet Science Journal

Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer

Sanaz Taromi, Florentine Lewens · 2017

Oncotarget

Metrics

213

Citations

46

References

Details

Published: Jan 01, 2006
Vol/Issue: 2(3)
Pages: 271-279

Authors

Cite This Article

Antonia Field-Smith, Gareth J Morgan, Faith E Davies (2006). Bortezomib (Velcade?) in the treatment of multiple myeloma. Therapeutics and Clinical Risk Management, 2(3), 271-279. https://doi.org/10.2147/tcrm.2006.2.3.271

Bortezomib (Velcade?) in the treatment of multiple myeloma

You May Also Like